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Background: In ovarian cancer, massive intraperitoneal dissemination is due to exfoliated tumor cells in ascites.
Tumor-initiating cells (TICs or cancer stem cells) and cells showing epithelial-mesenchymal-transition (EMT) are
particularly implicated. Spontaneous spherical cell aggregates are sometimes observed, but although similar to
those formed by TICs in vitro, their significance is unclear.
Methods: Cells freshly isolated from malignant ascites were separated into sphere samples (S-type samples, n=9)
and monolayer-forming single-cell suspensions (M-type, n=18). Using western blot, these were then compared for
expression of protein markers of EMT, TIC, and of cancer-associated fibroblasts (CAFs).
Results: S-type cells differed significantly from M-type by expressing high levels of E-cadherin and no or little
vimentin, integrin-β3 or stem cell transcription factor Oct-4A. By contrast, M-type samples were enriched for CD44,
Oct-4A and for CAF markers. Independently of M- and S-type, there was a strong correlation between TIC markers
Nanog and EpCAM. The CAF marker α-SMA correlated with clinical stage IV. This is the first report on CAF markers
in malignant ascites and on SUMOylation of Oct-4A in ovarian cancer.
Conclusions: In addition to demonstrating potentially high levels of TICs in ascites, the results suggest that the
S-type population is the less tumorigenic one. Nanoghigh/EpCAMhigh samples represent a TIC subset which may be
either M- or S-type, and which is separate from the CD44high/Oct-4Ahigh subset observed only in M-type samples.
This demonstrates a heterogeneity in TIC populations in vivo which has practical implications for TIC isolation based
on cell sorting. The biological heterogeneity will need to be addressed in future therapeutical strategies.
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Most patients with epithelial ovarian carcinoma (EOC)
are diagnosed with stage III or IV disease, i.e., when
dissemination is already at hand. Along with rapid
development of chemoresistant disease, this brings down
the 5-year disease-specific survival in EOC to 50% [1].
Dissemination is mainly abdominal via tumor cells in as-
cites. These are likely enriched for aggressive cells that
may have exfoliated not only from an excised primary
tumor but also from established and often numerous
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reproduction in any medium, provided the orAscitic ovarian cancer cells are proposed to undergo
epithelial-to-mesenchymal-transition (EMT) to a motile
phenotype with low levels of E-cadherin and higher
invasivity than the primary tumor cells [2,3]. They are
thus similar to blood- or lymph-borne circulating tumor
cells from other types of carcinoma. They are similar
also in that they represent a less studied but phenotypic-
ally and pathologically progressed stage compared to the
primary tumors.
Of importance for the present study, ascitic tumor
cells may occur as single-cell suspensions and sheet-like
cell aggregates, but occasionally also as compact spheres
in which individual cells cannot be discerned. Although
spheres have been associated with invasivity, e.g., in
in vitro models using artificially created spheroids froml Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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extensively characterized. Interestingly,”collective migra-
tion” of multicellular clusters of cancer cells has been
described as an enhanced type of metastatic behavior in
breast and colon cancer [7].
Sphere formation in vitro, dissemination and chemore-
sistance are in turn features associated with cancer stem
cells or tumor-initiating cells (TICs). TICs are now
regarded as a major cause of relapse in chemoresistant
cancer, and thus need to be identified both for prognos-
tic and therapeutic purposes [8-10]. In the experimental
in vitro setting, TIC identity is commonly based on
expression of two or three of a set of markers, and is
verified based on high tumorigenicity and/or serial
transplantation in nude mice. Irrespective of whether
TICs originate from stem cells or from a certain subpo-
pulation of cancer cells, they are regulated not only by
genetic but also by epigenetic and adaptational events
[11]. As part of adaptation to hypoxia, both TICs and
normal stem cells depend on glycolysis rather than
mitochondrial respiration for ATP. Importantly, hypoxia
has been shown to promote tumor”stemness” as well as
EMT [12,13], suggesting that in ascitic EOC spheres,
the hypoxic interior might enrich for TICs.
Cancer-associated fibroblasts (CAFs) represent yet
another parameter contributing to invasivity, metastasis
and chemoresistance [14]. Immunohistochemical ana-
lysis has shown absence of the CAF marker smooth
muscle actin (α-SMA) in normal ovarian tissue, whereas
the stroma of metastatic EOC tumors abounded in
CAFs [15].
To explore the molecular pathology of EOC ascitic
cell populations, we have here examined spheres and
single-cell populations that were isolated directly from
patients. The samples were compared in terms of
expression of metabolic, EMT, TIC and CAF markers,
and analysed by western blot in order to specifically as-
sess the net outcome of genetic, epigenetic and post-
translational effects. Importantly, freshly isolated human
EOC ascitic samples were used rather than subcultured
clones or cell lines, in which pheno- and genotypic drift
is a wellknown problem. As metabolic marker we used
mitochondrial β-F1-ATPsynthase, which reflects mito-
chondrial oxidative respiration and is downregulated at
the mRNA level in cancer cells [16]. It has prognostic
power on its own and in a ratio to Hsp60, i.e., as a bio-
energetic cell (BEC) index shown to be indicative of low
mitochondrial respiration and worse prognosis in, e.g.,
breast, lung and head-and-neck cancer [17,18]. We also
examined the mitochondrial transcription factor A,
TFAM, as it correlates with cellular mitochondrial con-
tent [19,20] and hence indirectly with oxidative metab-
olism. With regard to EMT and motility, we examined
E-cadherin and vimentin as standard markers ofepithelial and mesenchymal cells, respectively [7]. For
CAF markers, we used α-SMA and the receptor for
PDGFβ (PDGFβR) [14,15].
The significance and use of TIC markers requires
some consideration. For cell sorting/isolation purposes,
the surface proteins CD44, CD117 [10,21,22] and
EpCAM [23,24] are convenient antibody targets. They
also have intriguing dual functions as adhesion mole-
cules as well as receptors [11]. In TICs isolated from
primary breast cancer, shRNA-mediated knockdown
of CD44 led to decreased expression of stemness-
associated genes and to loss of tumorigenicity [25].
CD133 is another common TIC marker, including in
EOC [26]. However, CD133 has been questioned as
a marker of tumor-initiating capability in EOC
[22,27], and there is uncertainty as to the roles of
different splice and glycosylation forms and different
antibody clones [28,29].
TICs are also characterized by transcription factors
that are essential for stem cell self-renewal and pluripo-
tency, and which include Nanog and Oct-4A [10,11,22].
Several studies have used combinations of surface and
intracellular markers, e.g., CD44, CD117, Nanog and
Oct-4 to characterize TICs derived from experimental
EOC spheroids created in vitro [10]. The same report
also used ABCG2, the membrane efflux pump which
defines a side population enriched for TICs [30-32] and
which contributes to chemotherapy resistance [33].
In summary, it is clear that the biology and molecular
pathology of malignant ascites are of importance for the
understanding and treatment of this deadly disease [6].
There is, however, still a dearth of information on ascitic
cell subpopulations in vivo, i.e., isolated directly from
patients. Based on such material and on protein marker
profiles reflecting known phenotypic traits, our results
indicate potentially very high levels of circulating
TIC-type cells in malignant ascites and demonstrate
that ascitic spheres and monolayer-forming cells are
two distinct in vivo populations with different tumori-
genic potential, based on protein markers. For the first
time, the presence in malignant ascites of cancer-
associated fibroblasts is also indicated.
Methods
Patients, ascites and cell culture
Malignant ascites were collected from 22 ovarian cancer
patients (Table 1) at the Department of Gynecologic
Oncology, Karolinska University Hospital. The study
was approved by the Regional Ethics Committee of
Stockholm (EPN 2009/1897-31/1) and samples collected
with the consent of the patients.
Cells in the ascitic fluid were pelleted, resuspended in
PBS, and separated on a discontinuous gradient consist-
ing of (bottom to top) Lymphoprep (Axis-Shield, Oslo,
Table 1 Clinicopathologic characteristics of cancer
patients (n = 22)
No (%)
Carcinoma diagnosis
Epithelial ovarian 13 (59)
Fallopian tube 2 (9)












Not stated 5 (23)
Time of sampling




PFI < 6 months
Before start of 1st course recurrence treatment 7 (32)
During chemotherapy period 12 (55)
Type of cells
M-type only 13 (59)
S-type only 4 (18)
M and S 5 (23)
Median age at diagnosis 66.5 years
PFI; platinum-free interval.
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and Lymphoprep/Krebs HEPES Ring solution 1:2 (Krebs
HEPES Ring solution: 137 mM NaCl, 5.4 mM KCl, 0.34
mM Na2HPO4, 0.35 mM KH2PO4, 8 mM MgSO4, 1 mM
HEPES pH 7.4). Cells were then centrifuged at 1,500 × g
for 20 min.
Tumor cells were collected at the interphase between
the top and middle layer, washed and plated. When
spheres were present, these were collected by aspiration
the day after. We define spheres as compact spherical
aggregates where individual cells cannot be discerned.
Sheets/irregular aggregates of discernible and dispersible
cells have not been included in this category. All cells,
including the ovarian cancer cell line SKOV-3, which
originates from malignant ascites, were kept at +37°C in5% CO2 in RPMI1640 medium supplemented with
10% fetal calf serum, 1% penicillin-streptomycin, 2 mM
L-glutamine (Nordic Biolabs AB, Täby, Sweden). Finally,
for comparison with the physiological spheres from
patients, artificial spheroids were made in vitro from
freshly isolated tumor cells using previously described
methodology [34].
Western blot analysis and immunoprecipitation
Whole-cell lysates of monolayer-forming cell samples
and spheres, respectively, were made either immedi-
ately or after a maximum of one passage. This rapid
analysis is important for avoiding culture-induced
phenotypic drift. Protease and phosphatase inhibitor
cocktails (P2714 and P5726; Sigma-Aldrich Sweden AB,
Stockholm, Sweden) were added freshly to RIPA lysis
buffer (1% NP-40, 0.5% sodium deoxycholate, 0.1% so-
dium dodecyl sulfate, 0.004% sodium azide). Samples
were loaded for gel electrophoresis at 30 μg/sample.
Aliquots of the one and same SKOV-3 lysate were run
on each gel as an internal control. After separation,
proteins were transferred onto PVDF membranes, con-
firmed with Ponceau S staining. Membranes were
blocked for 1 h in 5% milk/PBS-Tween or 4% BSA/
TBS-Tween. All antibodies were diluted in blocking
agent. Membranes were incubated overnight at +4°C
with primary antibodies and then for 1 h at room
temperature with the appropriate HRP-conjugated sec-
ondary antibody (see complete list of antibodies in
Additional file 1: Table S1). Images were developed
with Western Lightning Plus-ECL (PerkinElmer, Upp-
lands Väsby, Sweden) and captured using Kodak M35
X-omat processor. Densitometry results are based on
median signals from raw-data tif-format images, and
normalized based on GAPDH levels and against the
same SKOV-3 lysate present on each membrane.
For immunoprecipitation, whole-cell lysates were
incubated with primary antibody to Oct-4A or SUMO-1
overnight at +4°C. Immunocomplexes were collected
using Protein A/G PLUS-Agarose beads (Santa Cruz
Biotechnology), and were then washed four times in
lysis buffer and further analyzed by western blotting.
See complete list of antibodies in Additional file 1:
Table S1.
Statistics
Densitometry data were analysed using the IBM
SPSS statistics 20.0 software (IBM Corp. NY, USA).
Shapiro-Wilk test was used to determine whether vari-
ables/groups were normally distributed. Between-group
comparisons were performed using the Independent
t-test or Mann–Whitney U test, when appropriate.
Spearman’s Rank Order correlation was used to test
association between variables. In all tests, a two-tailed








CD44 Vimentin 0.810 <0.001 **
E-cadherin 100 K 0.676 <0.001 **
E-cadherin CD44 −0.528 0.005 **
E-cadherin Vimentin −0.692 <0.001 **
EpCAM 100 K 0.494 0.009 **
EpCAM β-F1-ATPsynthase 0.700 <0.001 **
Nanog EpCAM 0.694 <0.001 **
Nanog β-F1-ATPsynthase 0.432 0.024 *
Nanog 100 K 0.425 0.027 *
1 All marker combinations were tested. Only those showing a significant
correlation are shown.
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<0.05 or <0.01 are represented with one and two aster-
isks, respectively, in the figures. Relevant statistics are
presented in Tables 2 and 3. Due to lack of material,
two samples (one M- and one S-type) could not be
analysed for expression of α-SMA and PDGFβ-R. This
was taken into account in the statistical analyses.
Results
Some but not all ascitic cell samples contain
spontaneously formed spheres
The clinicopathologic characteristics of the 22 patients
are shown in Table 1. The majority was serous adenocar-
cinoma and all patients had advanced stage of disease
(FIGO stages IIIC or IV). Three of the cases were newly
diagnosed, of which one was platinum-refractory and
two were chemosensitive, and 19 were in relapse.
The ascitic samples contained single cells, loose sheet-
like aggregates and sometimes spheres (for definition,
see Materials and Methods). Single-cell suspensions and
easily dispersed loose aggregates readily formed mono-
layer cultures. Such samples are henceforth called
M-type, and the isolated spheres are henceforth called
S-type. In contrast to loose aggregates, the spheres couldTable 2 Statistical analysis of relative protein expression as based on densitometry
A. Comparison of M- and S-type samples, using Mann–Whitney U test/Independent t-test
Variable Sample size (n)
Sample type
Median (IQR)1 Sample type Mann– Whitney U p-value Exact Sign.
(2-tailed)
M S M S
β-F1-ATPsynth. 18 9 0.74 (0.76) 0.66 (0.86) 72.0 0.659
100 K 18 9 1.9 (9.6) 29 (33.15) 33.0 0.012 *
ABCG2 18 9 0.17 (0.63) 0.06 (0.26) 52.5 0.148
CD44 18 9 0.13 (0.20) 0.00 (0.00) 8.50 <0.001 **
E-cadherin 18 9 0.71 (5.2) 8.6 (7.2) 31.0 0.009 **
Nanog 18 9 0.52 (0.72) 0.92 (2.21) 70.5 0.605
Oct-4A 18 9 1.1 (3.0) 0.02 (0.48) 26.0 0.003 **
SUMO-Oct-4A 18 9 0.96 (1.0) 0.45 (0.80) 34.0 0.014 *
TFAM 18 9 0.77 (1.0) 0.51 (2.0) 79.0 0.929
Vimentin 18 9 0.69 (0.8) 0.05 (0.10) 11.0 <0.001 **






M S M S
α-SMA 17 8 1.8(±1.1) 0.86(±0.30) 3.042 0.0062 **
EpCAM 18 9 0.90(±0.47) 0.87(±0.44) 0.130 0.8973






IIIC IV IIIC IV
α-SMA 17 8 1.1(±0.67) 2.3(±0.46) −2.401 0.0062 **
1 IQR: Inter-quartile range.
2 Equal variances not assumed.
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Figure 1 Spheres constitute a separate population. Ascitic cells
were isolated from ovarian cancer patient ascites and separated into
monolayer-forming single-cell suspensions (M-type samples; M) and
spontaneous spheres (S-type samples; S), all as described in Materials
and Methods. Lysates of each sample were analysed by western
blot, with GAPDH as loading control. As interblot reference, a lysate
(one and the same for all experiments) of the SKOV-3 cell line,
derived from EOC malignant ascites, was used. Numbers refer to
patients. A. Representative images of spheres, 40x magnification.
Left: immediately after isolation. Right: Dispersed spheres do not
form monolayers in culture, but continue to form spheres like this
one and which then detach from the few adherent cells seen in the
background. B. Top: Representative example of E-cadherin and
vimentin expression in paired M- and S-type samples, each pair from
one and the same patient. Below: The data on E-cadherin and
vimentin expression levels throughout the whole cohort are
summarized in box plots comparing the distribution of relative
expression of these proteins in all M (n = 18) and S (n = 9) samples,
respectively. Asterisks denote statistically significant differences
(Mann–Whitney U test). C. Representative examples of E-cadherin
and vimentin expression in paired M- and S-samples from two
patients, and artificial spheroids (AS) created in vitro using the M-
sample cells. D. Expression of integrin β3 in two paired M- and S-
type samples, each pair from one and the same patient.
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through a fine-mesh filter. Moreover, the resulting cells
would when plated sparsely never form monolayers but
rapidly formed spheres again, often by a proliferative”-
budding” and detachment from a few adherent cells(Figure 1A). We conclude that the S-type cells are not
senescent but proliferate as spheres rather than as
monolayer cells.
Five patient samples contained both M- and S-type
cells. These were prepared and analyzed as separate
samples. Four patient samples contained only S-type.
The study thus encompasses a total of 27 samples that
are either M (n= 18) or S (n= 9).
M- and S-type cells constitute separate populations
Western blots (exemplified in Figure 1B) and densi-
tometry analysis of the whole material showed that
E-cadherin expression was associated with S-type samples,
but not with M-type (p = 0.009), and the mesenchymal
marker vimentin with M- but not S-type (p = <0.001).
These and all other statistics presented here are sum-
marized in Tables 2 and 3.
To examine whether spherical growth per se was suffi-
cient to induce E-cadherin, artificial spheroids were cre-
ated from M-type samples, both from patient ascites
with only M-type cells as well as from ascites containing
both M- and S-type. The results showed that unlike the
spontaneous S-type spheres, the artificial spheroids did
not express E-cadherin (exemplified in Figure1C).
Integrin β3 has been shown to be upregulated in EOC
compared to normal ovarian surface epithelium [35] and
has also been suggested as a prognostic marker [36].
Here, integrin β3 was assessed in two of the patient sam-
ples that contained both M- and S-type cells, and integ-
rin β3 was expressed only in the M-type (Figure 1D).
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cells constitute two separate populations.
We initially hypothesized that due to internal hypoxia,
spheres would show lower levels of the mitochondrial
proteins β-F1-ATPsynthase and/or TFAM. This was
refuted, however, as M- and S-type did not differ with
respect to either protein (p = 0.659 and 0.929, respect-
ively; Tables 2 and 3).Higher levels of CAF markers in M-type samples correlate
with stage IV disease
Smooth muscle actin (α-SMA) and PDGFβ-R expression
characterize activated cancer-associated fibroblasts [14].
Significantly higher levels of α-SMA were observed in
M- compared to S-type samples (p = 0.006) (Figure 2A-B
and Tables 2 and 3). Moreover, 9/25 samples analyzed
showed PDGFβ-R expression, and all 9 were M-type
(Figure 2A and not shown), and 8/9 samples expressing
PDGFβ-R also expressed the ovarian cancer TIC marker
CD44 and high levels of stem cell transcription factor
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Figure 2 Presence of cancer-associated fibroblasts in ascites. A
representative western blots showing co-expression of PDGFβR and
α-SMA in paired M- and S-samples from three patients. In total 9/25
samples showed expression of PDGFβR, all of them M-type.
Numbers refers to patients. B. Box plots comparing the distribution
of relative expression of α-SMA in M- (n = 17) and S-type (n = 8)
samples (left) and in samples representing clinical stage IIIC (n = 17)
and IV (n = 8) at diagnosis (right). Asterisks denote statistically
significant difference (Independent t-test).Alpha-SMA was significantly higher in samples from
patients diagnosed with stage IV compared to stage IIIC (p
= 0.040). The clinical data (summarized in Table 1) were
used for examining associations between markers and, e.g.,
time to progression, platinum-free interval, survival etc.
We found that (p = 0.040) (Figure 2B; Tables 2 and 3). No
other significant correlation was found (not shown).
TIC surface markers: CD44 is expressed exclusively in
M-type samples
The TIC marker CD44 [15,23,37,38] was found only in
M-type samples (p < 0.001) (exemplified in Figure 3A;
Tables 2 and 3). Accordingly, it correlated inversely with
E-cadherin expression (rs = −0.528, p = 0.005) and
correlated strongly with vimentin expression (rs = 0.810,
p = <0.001) (Table 2). By contrast, M- and S-type did
not differ with regard to TIC markers EpCAM [23,24]
and ABCG2 [32] (p = 0.897 and 0.148, respectively;
Table 2 and 3). CD117 was expressed in 4/27 samples
and was not further analysed.
TIC transcription factors: Oct-4A and SUMO-Oct4A levels
are higher in M-type samples
We examined expression of stem cell transcription fac-
tors Oct-4A and Nanog. Of the three isoforms of Oct-4,
only Oct-4A is nuclear and crucial for stem cell renewal
[39]. SUMOylation of Oct-4A is an important regulatory
mechanism as it leads to increased stability and function
of the protein [40]. SUMO-Oct4A has to our knowledge
not been studied in ovarian cancer. We first identified
the SUMO-Oct4A band in SKOV-3 lysates using immu-
noprecipitation of SUMO and Oct-4A, respectively, fol-
lowed by western blotting for the same. A ~90 kDa band
corresponded to SUMO-Oct4A (Figure 3B).
In the patient samples, SUMO-Oct4A was observed at
varying levels in 24/27 samples while unmodified Oct-4A
was seen in 17/27 samples (exemplified in Figure 3C). M-
type samples showed higher expression than did S-type of
Oct-4A and SUMO-Oct-4A (p = 0.003 and 0.014, respect-
ively) (Figure 3D; Tables 2 and 3). By contrast, M- and S-
type did not differ with respect to Nanog (p = 0.605)
(Figure 3D; Tables 2 and 3).
There was a positive correlation between β-F1-
ATPsynthase and Nanog (rs = 0.432, p = 0.024; Tables 2
and 3), and between β-F1-ATPsynthase and EpCAM (rs
= 0.700, p = <0.001). Since Nanog and EpCAM also cor-
relate (rs = 0.694, p = <0.001), there is an association be-
tween these three markers, independently of sample type.
A cellular 100 kDa fragment of E-cadherin in S-type
samples
In addition to these transcriptional factors, we noted
that in 13/27 samples E-cadherin was cleaved to a 100
kDa fragment which can be seen in Figure 1B and 1C,
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Figure 3 TIC protein marker expression in M- and S-type
samples. A. Representative blot showing CD44 expression in M-
and S-type samples. Based on all samples, CD44 was associated with
M-type (p<0.001; Table 2). Numbers refer to patients. B. The SKOV-3
cell line was used for immunoprecipitation with antibodies to Oct-4
and to SUMO, respectively. Shown here is a representative western
blot of three immunoprecipitates made with antibodies to Oct-4,
SUMO and mouse IgG, respectively, and which were then probed
using anti-Oct-4A. Mouse IgG served as negative control. SUMO-Oct-
4A could be detected when probed with anti-SUMO (not shown).
The results were confirmed using two other cell lines (not shown).
Arrow: native ~40 kDa Oct-4A just above the 25 kDa IgG light chain.
IP: immunoprecipitation; WB: western blot probe; m-IgG: mouse IgG.
C. Oct-4A and SUMO-Oct-4A in M-type samples and paired samples
of M- and S-type. D. Box plots comparing the distribution of relative
expression of Oct-4A, SUMO-Oct-4A and Nanog, respectively, in all M
(n=18) and S (n=9) samples. Asterisks denote statistically significant
differences (Mann–Whitney U test).
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sion section, this is likely the calpain-cleaved form
shown by others to have lost the β- and γ-catenin bind-
ing sites [41]. Such cleavage potentially leads to nuclear
translocation of β-catenin and Wnt signaling involved in
TIC maintenance [42]. The 100 K form was significantly
higher in S-type samples than in M-type (p = 0.012)
and correlated with expression of EpCAM (rs = 0.494,
p = 0.009), Nanog (rs = 0.425, p = 0.027) and E-cadherin
(rs = 0.676, p = <0.001; Table 2 and 3).
Discussion
Compared to experimental studies on tumor-initiating
cells (TICs), the representation of TICs in the actual
human in vivo situation is less well studied. This fact,
and the nature of ovarian cancer ascitic cells as circulat-
ing and potentially metastatic cells, prompted us to
examine freshly isolated ascitic samples for expression
markers of EMT, TICs and cancer-associated fibroblasts
(CAFs).
Previous studies have suggested that EOC ascitic cell
spheres represent the invasive and/or metastasis-
forming subpopulation leading to recurrent disease [4,6].
This notion has in part been supported by in vitro work
on artificial spheroids, and is also based on the well-
known fact that TICs can be isolated from in vitro
spheroids cultured continuously in stem cell medium.
Indeed, our own initial hypothesis was that the spontan-
eous EOC ascitic spheres are similar to TIC spheroids
and that the hypoxic interiors of spheres would support
or harbor TIC-like cells.
However, our results show that the S-type populations
freshly isolated from patients were not only of an epithe-
lial and thus less invasive phenotype, but they were also
low in the EOC TIC marker CD44 and the stem cell
transcription factor Oct-4A and did not express CAF
markers. Compared to the M-type samples, the S-type
thus present a less tumorigenic profile. It may be noted,
however, that they likely represent a chemoresistant
population since chemotherapeutic drugs do not pene-
trate such multicellular structures [34,43].
Among M-type samples, two subtypes could be dis-
cerned: one that was similar to S-type but obviously lack-
ing some factor required for sphere formation in ascites,
and a second subtype that was CD44high/Oct-4Ahigh and
which in addition also expressed specific CAF markers.
In addition to other reports on CD44 as an EOC TIC
marker [10,21,22], the role of CD44 in regulating a TIC
phenotype was recently shown when shRNA-mediated
knockdown of CD44 caused breast cancer TICs to dif-
ferentiate and abolished their tumorigenicity in mice
[25]. Similarly, results of experimental knockdown of
Oct-4 have indicated its role in regulation of a TIC
phenotype [44].
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Oct-4Ahigh subtype of M is the more malignant one.
This is based on the roles of CD44 and Oct-4A in de-
fining TICs, on the motility/invasivity of vimentin-rich
tumor cells, and on the expression of CAF markers
α-SMA and PDGFβ-R.
In further support of this model, the inverse correl-
ation which we observed between CD44 and E-cadherin
may reflect the recent finding that in serial xenografts
of EOC tumors, the tumorigenic CD44high cells were
low/intermediate in E-cadherin [45]. Moreover, CAFs
may originate either as fibroblasts or from epithelial
cells that have undergone EMT [14]. Here, the ratio of
E-cadherin:vimentin in M-type samples and the
adherence-independence of these cells in vivo are both
in accordance with the latter scenario. Importantly, the
observed co-expression of PDGFβ-R and α-SMA fur-
ther strengthens the identity and presence of activated
CAFs, whose role(s) as direct promoters of metastasis,
angiogenesis and chemoresistance is increasingly clear
[14,15,46].
In line with such roles, we found that samples with a
diagnosis of clinical stage IV showed higher expression
of α-SMA than did samples from stage IIIC patients
(p= 0.040). This is in line with the recent finding that
CAFs promote EOC growth and metastasis in vivo [15].
It is also in line with stage IV being defined by
hematogenous metastasis to distant sites, e.g., to the
liver. Altogether, this is to our knowledge the first report
to indicate the presence of CAFs in EOC malignant
ascites.
Transcription factors generally make up only a minute
fraction of the entire cellular proteome, and TIC-
associated transcription factors an even smaller fraction
within a population. Yet we could easily detect Oct-4A
and Nanog in the present material, indicating significant
levels of TICs within the samples. It is likely of great
importance for this result that the samples were not
subcultured in vitro, where the differentiating condi-
tions and the consequent asymmetric proliferation of
TICs will soon dilute the levels of TIC markers.
We note that although Oct-4 was recently associated
with advanced FIGO stage and higher histological grade
in serous ovarian adenocarcinoma [47], the present
report is the first to show high expression in EOC of
Oct-4A, the isoform that is crucial for stem cell renewal
[39]. We are hence also first to show high expression in
EOC of the stabilized, and more active, SUMOylated
form [48] of Oct-4A. Indeed, 24/27 (89%) of the samples
expressed Oct-4A/SUMO-Oct4A. Moreover, and of im-
portance for data interpretation in further studies, we
found that in some samples virtually all Oct-4A was in
the ~90 kDa SUMOylated form. This demonstrates that
lack of ~40 kDa Oct-4A in a western blot does notnecessarily correspond to lack of the protein. Interest-
ingly, Ubc9 is the only SUMO-ligase required for
SUMO-Oct-4A [48], and it is upregulated in ovarian
cancer [49], although its prognostic potential has not
been investigated.
The 100 K is likely the calpain-cleaved 100 kDa
E-cadherin fragment that releases β-catenin allowing it
to translocate to the nucleus and participate in Wnt-like
signaling [41,50]. The antibody used here does not
recognize any other known intracellularly cleaved frag-
ment. Nor could the fragment be due to the well-studied
extracellular cleavage of E-cadherin that generates the
soluble extracellular form, sometimes known as gp80 or
sE-cad, which would not be found in cell lysates nor be
recognized by the antibody used. Moreover, the
remaining cellular fragment from sE-cad is around
37 kDa, i.e., not the one we observed. It would be inter-
esting to know whether 100 K is identical to the cyto-
plasmic E-cadherin observed at high levels in the
multipotent, tumorigenic epithelial-mesenchymal hybrid
subset of EOC tumors [45], and/or to internalized
E-cadherin leading to increased β-catenin/Wnt signaling
in EOC cells [51].
Like Oct-4A, Nanog is involved in stem cell renewal.
In EOC, Nanog expression in tumors has been shown to
correlate with clinical stage [52]. Here, Nanog correlated
with TIC marker EpCAM (rs= 0.694, p= <0.001) and
with 100 K (rs= 0.425, p= 0.027), but not with CD44 or
Oct-4A. The results thus show that TIC surface and
transcriptional markers do not necessarily coincide. This
in turn suggests that while abundant reports show that
cell sorting based on CD44 will enrich for TICs, there
may in vivo exist several subsets of TICs. Applied to
the present material, the model also suggests that the
Nanoghigh/EpCAMhigh samples represent a particular
TIC subset which may be either M- or S-type, and
which is separate from the CD44high/Oct-4Ahigh subset
observed only in M-type samples.
Conclusion
We have here demonstrated high expression of TIC
markers in malignant ascitic cells, and thereby poten-
tially high levels of TICs in ascites. M-type populations
expressing CAF markers are likely more aggressive or
tumorigenic than the S-type. Furthermore, Nanoghigh/
EpCAMhigh samples represent a particular TIC subset
which may be either M- or S-type, and which is separate
from the CD44high/Oct-4Ahigh subset observed only in
M-type samples. This may have practical implications
for TIC isolation based on cell sorting, since using a
particular set of markers may result in a particular sub-
set of TICs. It may moreover explain why the literature
can present different sets of markers to identify TICs.
The results also imply a biological heterogeneity that
Wintzell et al. BMC Cancer 2012, 12:359 Page 9 of 10
http://www.biomedcentral.com/1471-2407/12/359will need to be addressed in future therapeutical
strategies.
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